Zou W. · Zhang X. · Wang Y. · Yan L. · Wu X. · Yang R. · Li Y. · Zhang J. · Chen J.

Author affiliations

Department of Respiratory and Critical Care Medicine, Aerospace Center Hospital, Beijing, China

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Access via DeepDyve Unlimited fulltext viewing of this article Organize, annotate and mark up articles Printing and downloading restrictions apply

Select

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: February 24, 2022
Accepted: April 19, 2022
Published online: June 22, 2022

Number of Print Pages: 9
Number of Figures: 5
Number of Tables: 0

ISSN: 0031-7012 (Print)
eISSN: 1423-0313 (Online)

For additional information: https://www.karger.com/PHA

Abstract

Introduction: Abundant studies have disclosed that proteins can function as pivotal tumor promoters or suppressors in cancers’ progression. This work was planned to investigate the regulatory function of N-myristoyltransferase-1 (NMT1) on non-small cell lung cancer (NSCLC) and the underlying molecular mechanisms. Methods: The self-renewal abilities were assessed through a spheroid-formation assay. The tumorigenic abilities were examined through nude mice in vivo assay. The proteins’ expression was measured through Western blot. The NMT1 protein expression in tumor tissues was measured through an IHC assay. The cell migration and invasion was confirmed through a transwell assay. The IC50 was verified through a CCK-8 assay. The NMT1 mRNA expression in NSCLC tissues was detected through RT-qPCR. Results: It was demonstrated that NMT1 exhibited higher expression in spheroid cells. Additionally, NMT1 facilitated the stemness in NSCLC. It was also found that NMT1 accelerated NSCLC tumor metastasis and the resistance to cisplatin. Moreover, NMT1 activated the PI3K/AKT pathway to facilitate stemness in NSCLC. NMT1 was also higher in tumor tissues of NSCLC patients and resulted in a poor survival rate. Conclusion: NMT1 enhanced the stemness of NSCLC cells by activating the PI3K/AKT pathway. This discovery suggested that NMT1 may be a valid therapeutic biomarker for NSCLC.

© 2022 S. Karger AG, Basel

References Nanavaty P, Alvarez MS, Alberts WM. Lung cancer screening: advantages, controversies, and applications. Cancer Control. 2014 Jan;21(1):9–14. Mao Y, Yang D, He J, Krasna MJ. Epidemiology of lung cancer. Surg Oncol Clin N Am. 2016 Jul;25(3):439–45. Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018 Jan 24;553(7689):446–54. Naylor EC, Desani JK, Chung PK. Targeted therapy and immunotherapy for lung cancer. Surg Oncol Clin N Am. 2016 Jul;25(3):601–9. Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 2019 Aug;94(8):1623–40. Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review. JAMA. 2019 Aug 27;322(8):764–74. Yu Y, He J. Molecular classification of non-small-cell lung cancer: diagnosis, individualized treatment, and prognosis. Front Med. 2013 Jun;7(2):157–71. Nie X, Liu H, Ye W, Wei X, Fan L, Ma H, et al. LRP5 promotes cancer stem cell traits and chemoresistance in colorectal cancer. J Cell Mol Med. 2022 Feb;26(4):1095–112. Xie Q, Zhao S, Liu W, Cui Y, Li F, Li Z, et al. YBX1 enhances metastasis and stemness by transcriptionally regulating MUC1 in lung adenocarcinoma. Front Oncol. 2021;11:702491. Liu S, Bu X, Kan A, Luo L, Xu Y, Chen H, et al. SP1-induced lncRNA DUBR promotes stemness and oxaliplatin resistance of hepatocellular carcinoma via E2F1-CIP2A feedback. Cancer Lett. 2022 Mar 1;528:16–30. Mei J, Zhu C, Pan L, Li M. MACC1 regulates the AKT/STAT3 signaling pathway to induce migration, invasion, cancer stemness, and suppress apoptosis in cervical cancer cells. Bioengineered. 2022 Jan;13(1):61–70. Wang X, He H, Rui W, Zhang N, Zhu Y, Xie X. TRIM38 triggers the uniquitination and degradation of glucose transporter type 1 (GLUT1) to restrict tumor progression in bladder cancer. J Transl Med. 2021 Dec 14;19(1):508. Meinnel T, Dian C, Giglione C. Myristoylation, an ancient protein modification mirroring eukaryogenesis and evolution. Trends Biochem Sci. 2020 Jul;45(7):619–32. Martin DD, Beauchamp E, Berthiaume LG. Post-translational myristoylation: fat matters in cellular life and death. Biochimie. 2011 Jan;93(1):18–31. Wang B, Dai T, Sun W, Wei Y, Ren J, Zhang L, et al. Protein N-myristoylation: functions and mechanisms in control of innate immunity. Cell Mol Immunol. 2021 Apr;18(4):878–88. O'Callaghan DW, Haynes LP, Burgoyne RD. High-affinity interaction of the N-terminal myristoylation motif of the neuronal calcium sensor protein hippocalcin with phosphatidylinositol 4,5-bisphosphate. Biochem J. 2005 Oct 15;391(Pt 2):231–8. Chen W, Salari H, Taylor MC, Jost R, Berkowitz O, Barrow R, et al. NMT1 and NMT3 N-methyltransferase activity is critical to lipid homeostasis, morphogenesis, and reproduction. Plant Physiol. 2018 Aug;177(4):1605–28. Selvakumar P, Kumar S, Dimmock JR, Sharma RK. NMT1 (N-myristoyltransferase 1). Atlas Genet Cytogenet Oncol Haematol. 2011 Jan 7;15(7):570–5. Mackey JR, Lai J, Chauhan U, Beauchamp E, Dong WF, Glubrecht D, et al. N-myristoyltransferase proteins in breast cancer: prognostic relevance and validation as a new drug target. Breast Cancer Res Treat. 2021 Feb;186(1):79–87. Deng L, Gao X, Liu B, He X, Xu J, Qiang J, et al. NMT1 inhibition modulates breast cancer progression through stress-triggered JNK pathway. Cell Death Dis. 2018 Nov 16;9(12):1143. Sun Y, Guan Z, Sheng Q, Duan W, Zhao H, Zhou J, et al. N-myristoyltransferase-1 deficiency blocks myristoylation of LAMTOR1 and inhibits bladder cancer progression. Cancer Lett. 2022 Mar 31;529:126–38. Ma X, Yuan Y, Lu J, Li M, Yu Y, Liu J, et al. Long noncoding RNA ANCR promotes migration, invasion, EMT progress and stemness of nasopharyngeal carcinoma cells via the miR-4731-5p/NMT1 axis. Pathol Res Pract. 2021 Aug;224:153540. Kim S, Alsaidan OA, Goodwin O, Li Q, Sulejmani E, Han Z, et al. Blocking myristoylation of Src inhibits its kinase activity and suppresses prostate cancer progression. Cancer Res. 2017 Dec 15;77(24):6950–62. Zhu G, Wang F, Li H, Zhang X, Wu Q, Liu Y, et al. N-Myristoylation by NMT1 Is POTEE-dependent to stimulate liver tumorigenesis via differentially regulating ubiquitination of targets. Front Oncol. 2021;11:681366. Dawood S, Austin L, Cristofanilli M. Cancer stem cells: implications for cancer therapy. Oncology. 2014 Dec;28(12):1101–7, 1110. Nassar D, Blanpain C. Cancer stem cells: basic concepts and therapeutic implications. Annu Rev Pathol. 2016 May 23;11:47–76. Yuan Z, Xiu C, Liu D, Zhou G, Yang H, Pei R, et al. Long noncoding RNA LINC-PINT regulates laryngeal carcinoma cell stemness and chemoresistance through miR-425-5p/PTCH1/SHH axis. J Cell Physiol. 2019 Dec;234(12):23111–22. Huang Z, Shen G, Gao J. CDK1 promotes the stemness of lung cancer cells through interacting with Sox2. Clin Transl Oncol. 2021 Sep;23(9):1743–51. Chi J, Zhang H, Hu J, Song Y, Li J, Wang L, et al. AGR3 promotes the stemness of colorectal cancer via modulating Wnt/β-catenin signalling. Cell Signal. 2020 Jan;65:109419. Wu X, Wang Y, Zhong W, Cheng H, Tian Z. RNA binding protein RNPC1 suppresses the stemness of human endometrial cancer cells via stabilizing MST1/2 mRNA. Med Sci Monit. 2020 Feb 23;26:e921389. Xu L, Zhang X, Wang Z, Zhao X, Zhao L, Hu Y. Kinesin family member 2A promotes cancer cell viability, mobility, stemness, and chemoresistance to cisplatin by activating the PI3K/AKT/VEGF signaling pathway in non-small cell lung cancer. Am J Transl Res. 2021;13(4):2060–76. Yang Y, Zhang T, Wu L. TUFT1 facilitates metastasis, stemness, and vincristine resistance in colorectal cancer via activation of PI3K/AKT pathway. Biochem Genet. 2021 Aug;59(4):1018–32. Yang Z, Zhang C, Qi W, Cui Y, Xuan Y. GLI1 promotes cancer stemness through intracellular signaling pathway PI3K/Akt/NFκB in colorectal adenocarcinoma. Exp Cell Res. 2018 Dec 15;373(1–2):145–54. Gao XF, He HQ, Zhu XB, Xie SL, Cao Y. LncRNA SNHG20 promotes tumorigenesis and cancer stemness in glioblastoma via activating PI3K/Akt/mTOR signaling pathway. Neoplasma. 2019 Jul 23;66(4):532–42. Pan S, Sun Y, Sui D, Yang T, Fu S, Wang J, et al. Lobaplatin promotes radiosensitivity, induces apoptosis, attenuates cancer stemness and inhibits proliferation through PI3K/AKT pathway in esophageal squamous cell carcinoma. Biomed Pharmacother. 2018 Jun;102:567–74. Article / Publication Details

First-Page Preview

Received: February 24, 2022
Accepted: April 19, 2022
Published online: June 22, 2022

Number of Print Pages: 9
Number of Figures: 5
Number of Tables: 0

ISSN: 0031-7012 (Print)
eISSN: 1423-0313 (Online)

For additional information: https://www.karger.com/PHA

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.